Traders should monitor for immediate downward pressure on RVPH shares due to dilution and the overhang from short-term exercisable warrants. The Series H warrants (12-month expiry) create near-term share supply risk if exercised or if investors sell into the market in anticipation.
RVPH drugs
RVPH drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 19 $0.8300entry
- T+1 · 8mo ago −3.61%α −1.87% · $0.8000
- T+5 · 8mo ago −6.02%α −3.81% · $0.7800
- T+20 · 7mo ago +2.41%α −5.21% · $0.8500
- T+60 · 5mo ago −15.66%α −30.01% · $0.7000
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Reviva Pharmaceuticals (RVPH) announced the pricing of a public offering of 6,666,667 shares of common stock and accompanying warrants to raise approximately $10 million in gross proceeds. The funds will be used to support the Phase 3 RECOVER-2 trial for brilaroxazine in schizophrenia, along with general corporate purposes. The offering includes dual tranches of warrants exercisable immediately at $1.50 per share, with differing expiration terms.
Key Financial Metrics
Key Facts
- Reviva is raising approximately $10 million through a public offering of 6,666,667 shares and warrants.
- Each share is sold with two warrants: Series G (5-year term) and Series H (12-month term), both exercisable at $1.50.
- The offering is priced at $1.50 per combined unit, below typical market thresholds for sustainable biotech financing.
- Proceeds will fund the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia and general corporate needs.
- A.G.P./Alliance Global Partners is the sole placement agent; closing expected March 20, 2026.
Financial Impact
Approximately $10 million in gross proceeds, with significant near-term dilution from short-term warrants.
Risk Factors
- High dilution risk from immediate exercisability of both warrant series, especially the 12-month Series H warrants.
- Low offering price of $1.50 suggests weak investor demand or distressed financing terms.
- Market cap of $14M indicates high risk of volatility and potential for further dilutive offerings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258719 |
Track record
12 reports on RVPH
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 No price data
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.3400 Now $0.3504 +3.07% settles Feb 11
- Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
- Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
- May 13, 202626w ago Press Release Bearish 7/10 Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
- May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
- Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
- Mar 30, 202633w ago Press Release Mixed 6/10 Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
- Mar 18, 202634w ago Press Release Bearish 6/10 Viewing Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers